πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

2,762 results for β€œCTI” Clear

  1. HS-IT101 Injection

    Qingdao University

    Solid Tumor

    phase 1 small molecule active

    1 trial

  2. HSV 2 Formulation 1

    Lxo Ireland Designated Activity Company

    Genital Herpes

    phase 1 mab terminated

    1 trial

  3. HTLP-onco-adult - A phase I/II Study evaluating the safety and the efficacy of Human T Lymphoid Progenitor (HTLP) injection to accelerate immune reconstitution after umbilical cord blood (UCB) transplantation in adult patients with hematologic malignancies

    Pari Pharma GmbH

    hematologic malignancies ; acute myeloid leukemias

    phase 1 other active

    1 trial

  4. HWS116 Injection

    BRIGHT MINDS BIOSCIENCES INC.

    Advanced Solid Tumors

    phase 1 small molecule active

    1 trial

  5. Hemay005 tablet

    Anhui Hemay Pharmaceutical Co., Ltd

    Chronic Obstructive Pulmonary Disease

    phase 1 small molecule completed

    1 trial

  6. Human Anti-PD-L1 Monoclonal Antibody Injection (LDP) Combined with Recombinant Anti-EGFR Human Mouse Chimeric Monoclonal Antibody Injection (CDP1)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Advanced Malignant Tumor

    phase 1 small molecule active

    1 trial

  7. Human BCMA targeted T Cells Injection

    The First People's Hospital of Lianyungang

    Multiple Myeloma

    phase 1 small molecule active

    1 trial

  8. IASO206 injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Relapsed/Refractory Multiple Myeloma (RRMM)

    phase 1 small molecule active

    1 trial

  9. IASO206 injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Autoimmune Hemolytic Anemia

    phase 1 mab active

    1 trial

  10. IBR733 Cell Injection

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 1 mab active

    1 trial

  11. ID-LV305

    Lxo Ireland Designated Activity Company

    Melanoma - Currently Enrolling

    phase 1 mab completed

    1 trial

  12. IDC-G305

    Lxo Ireland Designated Activity Company

    Melanoma

    phase 1 mab completed

    1 trial

  13. IL-22BP mRNA vaccine injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Refractory Malignant Solid Tumors

    phase 1 mab active

    1 trial

  14. IMM-BCP-01

    United Therapeutics Europe Ltd

    SARS-CoV2 Infection

    phase 1 small molecule terminated

    1 trial

  15. INAVAC (Vaksin Merah Putih - UA- SARS CoV-2 (Vero Cell Inactivated) 5 ΞΌg

    Hospital Authority, Hong Kong

    COVID-19 Pandemic

    phase 1 mab active

    1 trial

  16. In situ injection of anti-angiogenics in patients with brain arteriovenous malformations not eligible for exclusion treatment: phase I trial (BLITZ)

    Pari Pharma GmbH

    Cardiology and vascular disease

    phase 1 other active

    1 trial

  17. Inactivated Enterovirus Type 71 Vaccine

    Sinovac Research and Development Co.,

    Infection; Viral, Enterovirus

    phase 1 mab completed

    1 trial

  18. Inactive Marijuana (0% THC)

    BRIGHT MINDS BIOSCIENCES INC.

    Marijuana Use Disorder

    phase 1 small molecule completed

    1 trial

  19. Individualized caffeine cessation instructions

    BRIGHT MINDS BIOSCIENCES INC.

    Self-identified Problematic Caffeine Use

    phase 1 other completed

    1 trial

  20. Influenza A/Texas/71/2017 (H3N2)

    United Therapeutics Europe Ltd

    Influenza Viral Infections

    phase 1 mab completed

    1 trial

  21. Infudopa i.v.

    Lxo Ireland Designated Activity Company

    Parkinson Disease

    phase 1 small molecule completed

    1 trial

  22. Insulin degludec injection, RD15003

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Type 2 Diabetes

    phase 1 mab completed

    1 trial

  23. Interventional, open-label, single-group, long-term follow-up trial of Lu AG22515 in patients with moderate-to-severe Thyroid Eye Disease

    H. Lundbeck A/S

    Active, moderate-to-severe TED

    phase 1 other active

    1 trial

  24. Investigating the pharmacokinetics of petrelintide using different drug product concentrations in participants with a BMI β‰₯27.0 kg/m2

    Zealand Pharma A/S

    Weight reduction

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources